Skip to main content

KAT3B/p300 Antibody

Novus Biologicals, part of Bio-Techne | Catalog # NBP1-87693

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP1-87693
NBP1-87693-25ul

Key Product Details

Species Reactivity

Validated:

Human

Predicted:

Mouse (92%), Rat (91%). Backed by our 100% Guarantee.

Applications

Validated:

Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin

Cited:

ELISA

Label

Unconjugated

Antibody Source

Polyclonal Rabbit IgG

Concentration

Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.

Product Specifications

Immunogen

This antibody was developed against Recombinant Protein corresponding to amino acids: TQSTGMMNSPVNQPAMGMNTGMNAGMNPGMLAAGNGQGIMPNQVMNGSIGAGRGRQNMQYPNPGMGSAGNLLTEPLQQGSPQMGGQTGLRGPQPLKMGMMNNPNPYGSPYTQNPGQQ

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Scientific Data Images for KAT3B/p300 Antibody

Immunocytochemistry/ Immunofluorescence: KAT3B/p300 Antibody [NBP1-87693]

Immunocytochemistry/ Immunofluorescence: KAT3B/p300 Antibody [NBP1-87693]

Immunocytochemistry/Immunofluorescence: KAT3B/p300 Antibody [NBP1-87693] - Immunofluorescent staining of human cell line U-2 OS shows localization to nucleoplasm.
KAT3B/p300 Antibody

Immunohistochemistry-Paraffin: KAT3B/p300 Antibody [NBP1-87693] -

Immunohistochemistry-Paraffin: KAT3B/p300 Antibody [NBP1-87693] -Staining of human cerebellum shows strong nuclear positivity in Purkinje cells.
KAT3B/p300 Antibody

Immunohistochemistry-Paraffin: KAT3B/p300 Antibody [NBP1-87693] -

Immunohistochemistry-Paraffin: KAT3B/p300 Antibody [NBP1-87693] -Staining of human testis shows strong nuclear positivity in a subset of cells in seminiferous ducts.

Applications for KAT3B/p300 Antibody

Application
Recommended Usage

Immunocytochemistry/ Immunofluorescence

0.25-2 ug/ml

Immunohistochemistry

1:20 - 1:50

Immunohistochemistry-Paraffin

1:20 - 1:50
Application Notes
For IHC-Paraffin, HIER pH 6 retrieval is recommended. ICC/IF, Fixation Permeabilization: Use PFA/Triton X-100.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Immunogen affinity purified

Formulation

PBS (pH 7.2) and 40% Glycerol

Preservative

0.02% Sodium Azide

Concentration

Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: p300

p300 is a relatively stable and ubiquitously expressed nuclear phosphoprotein which is conserved among a variety of mammalian species. It is actively synthesized and phosphorylated in both quiescent and proliferating cells. Cyclic AMP-responsive enhancer binding protein (CREB) binding protein (CBP) and p300 are closely related transcriptional coactivators and have been shown to directly interact with many different DNA-binding transcription factors including nuclear hormone receptors, CREB, c-Fos, C-Jun/v-Jun, c-Myb/v-Myb, TFIIB and MyoD. Both CBP and p300 have been shown to display histone acetyltransferase (HAT) activity, capable of acetylating all four core histone particles in nucleosomes. As a result of HAT activity, it has been suggested CBP and p300 may play a direct role in activating chromatin for transcription.

Long Name

E1A-binding Protein p300

Alternate Names

EP300

Gene Symbol

EP300

Additional p300 Products

Product Documents for KAT3B/p300 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for KAT3B/p300 Antibody

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...